Just days after a CEO shake-up, Madrigal Pharmaceuticals has shared that the FDA has given its nonalcoholic steatohepatitis (NASH) drug priority review and that the agency doesn’t plan on holding an ...
The NDA is supported by two 2 positive interim analyses from the phase 3 REGENERATE trial that included patients with biopsy-proven stage 2 or 3 liver fibrosis due to NASH. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback